REPLIMUNE GROUP INC (REPL)
US76029N1063 - Common Stock
22.56 -0.29 (-1.27%)
After market: 22.56 0 (0%)
Fundamental Rating
Taking everything into account, REPL scores 3 out of 10 in our fundamental rating. REPL was compared to 625 industry peers in the Biotechnology industry. REPL has a great financial health rating, but its profitability evaluates not so good. REPL is valued expensive and it does not seem to be growing.
Note: REPL has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
The Piotroski-F score of REPL is 3.00. This is a low score and indicates issues in the health and profitability of REPL.
VS Industry
Valuation
Valuation Rating
With a price book ratio of 2.35, REPL is valued correctly.
When comparing the price book ratio of REPL to the average industry price book ratio of 2.03, REPL is valued in line with its industry peers.
The Price/Earnings Ratio is negative for REPL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for REPL. No positive earnings are expected for the next year.
VS Industry
Price/Book (2.35) VS Industry: 44% outperformed.
280.70
0.05
Growth
Growth Rating
The Earnings Per Share is expected to grow by 39.44% on average over the next 5 years. This is a very strong growth
The earnings per share for REPL have decreased strongly by -32.74% in the last year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -32.74% | 1.74% | -7.77% | 12.81% | 39.44% |
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Health
Health Rating
REPL has a Current Ratio of 17.52. This indicates that REPL is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio of REPL is much better than the industry average of 5.53. REPL has a better rating than 90% of its industry peers.
REPL has a Quick Ratio of 17.52. This indicates that REPL is financially healthy and has no problem in meeting its short term obligations.
The Quick Ratio of REPL is much better than the industry average of 5.37. REPL has a better rating than 90% of its industry peers.
An Altman-Z score of 7.76 indicates that REPL is not in any danger for bankruptcy at the moment.
The Altman-Z score of REPL is much better than the industry average of -1.05. REPL has a better rating than 82% of its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.00, REPL is more dependent on financing than its industry peers.
We won't put much weight on the industry comparison as REPL has a very low Debt to Equity (0.09).
We won't put much weight on the industry comparison as REPL has a very low Debt to Equity (0.09).
REPL has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of REPL.
VS Industry
Debt/Equity (0.09) VS Industry: 24% outperformed.
22.69
0.00
Quick Ratio (17.52) VS Industry: 90% outperformed.
0.02
87.97
Current Ratio (17.52) VS Industry: 90% outperformed.
0.04
87.97
Altman-Z (7.76) VS Industry: 82% outperformed.
-296.18
330.04
Dividend
Dividend Rating
No dividends for REPL!.
REPLIMUNE GROUP INC
NASDAQ:REPL (6/8/2023, 3:14:14 PM)
After market: 22.56 0 (0%)22.56
-0.29 (-1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-18 2023-05-18/bmo
Earnings (Next)08-02 2023-08-02/bmo
Inst Owners93.04%
Inst Owner Change11.55%
Ins Owners8.64%
Ins Owner Change7.21%
Market Cap1.30B
Analysts86.25
Price Target53.04 (135.11%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.33%
Min EPS beat(2)-7.68%
Max EPS beat(2)10.33%
EPS beat(4)2
Avg EPS beat(4)-3.83%
Min EPS beat(4)-18.95%
Max EPS beat(4)10.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)-0.21%
PT rev (3m)2.86%
EPS NQ rev (1m)-16.08%
EPS NQ rev (3m)-13.93%
EPS NY rev (1m)0%
EPS NY rev (3m)14.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-40.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.35 | ||
| P/tB | 2.35 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3
EYN/A
EPS(NY)-2.95
Fwd EYN/A
FCF(TTM)-2.26
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpSN/A
BVpS9.61
TBVpS9.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset TurnoverN/A
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 92.77% | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.52 | ||
| Quick Ratio | 17.52 | ||
| Altman-Z | 7.76 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)113.78%
Cap/Depr(5y)661.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-32.74%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-23.33%
EPS Next Y1.74%
EPS Next 2Y-7.77%
EPS Next 3Y12.81%
EPS Next 5Y39.44%
Revenue growth 1YN/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.02%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-54.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.82%
OCF growth 3YN/A
OCF growth 5YN/A
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA